Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan.
Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
BMC Pulm Med. 2023 Apr 26;23(1):146. doi: 10.1186/s12890-023-02418-3.
Although cases of respiratory bacterial infections associated with coronavirus disease 2019 (COVID-19) have often been reported, their impact on the clinical course remains unclear. Herein, we evaluated and analyzed the complication rates of bacterial infections, causative organisms, patient backgrounds, and clinical outcome in Japanese patients with COVID-19.
We performed a retrospective cohort study that included inpatients with COVID-19 from multiple centers participating in the Japan COVID-19 Taskforce (April 2020 to May 2021) and obtained demographic, epidemiological, and microbiological results and the clinical course and analyzed the cases of COVID-19 complicated by respiratory bacterial infections.
Of the 1,863 patients with COVID-19 included in the analysis, 140 (7.5%) had respiratory bacterial infections. Community-acquired co-infection at COVID-19 diagnosis was uncommon (55/1,863, 3.0%) and was mainly caused by Staphylococcus aureus, Klebsiella pneumoniae and Streptococcus pneumoniae. Hospital-acquired bacterial secondary infections, mostly caused by Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia, were diagnosed in 86 patients (4.6%). Severity-associated comorbidities were frequently observed in hospital-acquired secondary infection cases, including hypertension, diabetes, and chronic kidney disease. The study results suggest that the neutrophil-lymphocyte ratio (> 5.28) may be useful in diagnosing complications of respiratory bacterial infections. COVID-19 patients with community-acquired or hospital-acquired secondary infections had significantly increased mortality.
Respiratory bacterial co-infections and secondary infections are uncommon in patients with COVID-19 but may worsen outcomes. Assessment of bacterial complications is important in hospitalized patients with COVID-19, and the study findings are meaningful for the appropriate use of antimicrobial agents and management strategies.
虽然与 2019 年冠状病毒病(COVID-19)相关的呼吸道细菌感染病例经常被报道,但它们对临床病程的影响尚不清楚。在此,我们评估和分析了日本 COVID-19 患者中细菌感染的合并症发生率、病原体、患者背景和临床结局。
我们进行了一项回顾性队列研究,纳入了来自参与日本 COVID-19 工作组的多个中心的 COVID-19 住院患者(2020 年 4 月至 2021 年 5 月),并获得了人口统计学、流行病学和微生物学结果以及临床病程,并分析了 COVID-19 合并呼吸道细菌感染的病例。
在纳入分析的 1863 例 COVID-19 患者中,有 140 例(7.5%)合并呼吸道细菌感染。COVID-19 诊断时的社区获得性合并感染并不常见(55/1863,3.0%),主要由金黄色葡萄球菌、肺炎克雷伯菌和肺炎链球菌引起。在 86 例患者中诊断出医院获得性细菌继发性感染,主要由金黄色葡萄球菌、铜绿假单胞菌和嗜麦芽窄食单胞菌引起。医院获得性继发性感染病例常伴有与严重程度相关的合并症,包括高血压、糖尿病和慢性肾脏病。研究结果表明,中性粒细胞-淋巴细胞比值(>5.28)可能有助于诊断呼吸道细菌感染并发症。患有社区获得性或医院获得性继发性感染的 COVID-19 患者的死亡率显著增加。
COVID-19 患者中呼吸道细菌合并感染和继发性感染并不常见,但可能会使病情恶化。对住院 COVID-19 患者进行细菌并发症评估很重要,研究结果对合理使用抗菌药物和管理策略具有重要意义。